- Home
- LNKB vs FENC Comparison
LNKB vs FENC Comparison
Compare LNKB & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- FENC
- Stock Information
- Founded
- LNKB 2018
- FENC 1996
- Country
- LNKB United States
- FENC United States
- Employees
- LNKB N/A
- FENC N/A
- Industry
- LNKB
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LNKB
- FENC Health Care
- Exchange
- LNKB Nasdaq
- FENC Nasdaq
- Market Cap
- LNKB 277.1M
- FENC 225.4M
- IPO Year
- LNKB N/A
- FENC 2001
- Fundamental
- Price
- LNKB $7.21
- FENC $9.00
- Analyst Decision
- LNKB Strong Buy
- FENC Strong Buy
- Analyst Count
- LNKB 1
- FENC 2
- Target Price
- LNKB $9.00
- FENC $13.50
- AVG Volume (30 Days)
- LNKB 39.1K
- FENC 67.3K
- Earning Date
- LNKB 10-27-2025
- FENC 11-06-2025
- Dividend Yield
- LNKB 4.16%
- FENC N/A
- EPS Growth
- LNKB N/A
- FENC N/A
- EPS
- LNKB 1.01
- FENC N/A
- Revenue
- LNKB $121,982,000.00
- FENC $33,302,000.00
- Revenue This Year
- LNKB $18.26
- FENC $0.96
- Revenue Next Year
- LNKB N/A
- FENC $51.71
- P/E Ratio
- LNKB $7.14
- FENC N/A
- Revenue Growth
- LNKB 79.01
- FENC N/A
- 52 Week Low
- LNKB $6.00
- FENC $3.96
- 52 Week High
- LNKB $7.98
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- LNKB 50.32
- FENC 57.23
- Support Level
- LNKB $7.12
- FENC $8.73
- Resistance Level
- LNKB $7.46
- FENC $9.07
- Average True Range (ATR)
- LNKB 0.19
- FENC 0.34
- MACD
- LNKB -0.00
- FENC 0.06
- Stochastic Oscillator
- LNKB 41.42
- FENC 84.63
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.